

Alternative-Based Thresholding: A Simulation Study

Jasper Degryse^a, Ruth Seurinck^a, Joke Durnez^a and Beatrijs Moerkerke^a

^a Department of Data Analysis, Ghent University, Belgium

1. Functional Regions of Interest (fROI)

Advantages & applications:

- Increased sensitivity^[1]
- Input for further hypothesis testing: connectivity, TMS, biomarker,...




Figure 1 : Example of an fROI (left = coronal, right = axial). Identifying hMT/V5+ in 9 subjects^[4].

2. fROIs and thresholding

- We still need to correct for multiple testing in fROI (e.g., FWE, FDR,...): the chance on a false positive (FP) increases with the the number of voxels tested.
- We want to avoid both FP and false negatives (FN) (see Figure 2).
- Current thresholding only focuses on avoiding FP by testing against H_0 (0 % BOLD signal change).
- FP rate is controlled directly, but not the FN rate. However, thresholding induces a trade-off between FP and FN.
 - Lenient threshold: increase in FP and decrease in FN^[1]
 - Stringent threshold: decrease in FP and increase in FN^[1]
- More FP \Rightarrow overestimation
- More FN \Rightarrow underestimation




Figure 2 : Illustration of FP, or overestimation, and FN, or underestimation, in the test result with respect to the ground truth.

3. Alternative-based thresholding procedure (ABTP)^[2]

- Test against both H_0 and H_1 ^[2] to control both FP and FN rate.
- H_1 is specified by Δ_1 , the magnitude of the effect (in % BOLD signal change) expected under true activation, with $\Delta_1 \sim \mathcal{N}(\mu_{\Delta_1}, \tau^2)$ ^[2].
- The procedure leads to two measures of evidence: classical p -value p_0 and alternative p -value p_1 .
- The combination of thresholding these p -values ($p_0 \leq \alpha$; $p_1 \geq \beta$) results in a layered statistical parametric map (LSPM) with four layers.




Figure 3 : Visualization of p_0 and p_1 (top), and of the different types of voxels or layers (middle & bottom).

- p_0 : the smaller, the more evidence against H_0
- p_1 : the smaller, the more evidence against H_1
- Active:** strong evidence against null of no activation
- Inactive:** activity confidently excluded
- Uncertain:** activity not confidently excluded
- Practically Insignificant:** activity not clinically significant

4. Method simulations

- 500 single subject data sets (resolution: $30 \times 30 \times 30$; isotropic voxels: 1mm; sphere)
- 600 scans, TR of 2s
- Blocked ON/OFF design, 20s/block
- Smoothed with FWHM of 6mm
- Gaussian white noise added
- Classic testing: FDR correction at 0.05
- Manipulated parameters (ABTP): true underlying effect size, contrast to noise ratio, α , β and τ

5. Results




Figure 4 : Visual presentation of the LSPM. The greener the voxel is, the more it occurred in the layer that is shown over all simulations.




Figure 5 : False positives (Type I errors) and False negatives (Type II errors) for both the classic testing procedure and the ABTP.

Figure 6 : The number of voxels in the uncertainty layer (above) that are truly active (left bottom) or truly inactive (right bottom).

6. Discussion & conclusions

- The number of FP in the LSPM corresponded with uncorrected testing with $\alpha = .05$, but dropped to that of the FDR corrected testing when $\alpha = 0.001$.
- Importantly, the overall number of FN in the LSPM was lower than in both the uncorrected and FDR corrected classic testing procedure.
- With increasing β or decreasing τ , the number of FN increased and the number of FP decreased.
- The uncertainty layer consisted of more voxels as α and β decreased and τ increased. The number of truly inactive voxels in this layer was consistently larger than the number of truly active voxels for all parameter values.

Conclusions

- The greatest advantage in using the ABTP is the decrease of FN, compared to both the uncorrected and FDR corrected classic testing methods.
- When α and β are adjusted appropriately, the number of FP can also be reduced.

7. References

- Duncan & Devlin, (2011). *Neuroimage*, 57
- Durnez, Moerkerke, Bartsch, & Nichols (2013). *CABN*, 13
- Nieto-Castanon, & Fedorenko (2012). *Neuroimage*, 63
- Seurinck, de Lange, Achten & Vingerhoets (2011). *JCN*, 23